Impact of Cognitive Behavioral Intervention on Adherence and Quality of Life of Epileptic Patients
Study Details
Study Description
Brief Summary
The purpose of this interventional study is to assess the impact of pharmacist-led cognitive behavioral intervention in epileptic patients. The main questions are:
-
If pharmacist-led cognitive behavioral therapy can help in improving patient medication adherence?
-
How will the cognitive behavioral therapy impact the quality of life of the patients?
Participants of this study will be provided basic or advanced level counselling and educational material as part of their routine pharmacy visit.
Researchers will compare the two groups (Basic and advanced) to see which of the two groups are better in term of medication adherence and quality of life.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
The purpose of the study is to investigate whether incorporation of pharmacist-led cognitive behavioral therapy (CBT) to the treatment of epileptic patients can result in better adherence to anti epileptic drugs. In order to manage epilepsy effectively, medication adherence is essential. Missed doses or irregular drug use can increase the frequency of seizures and reduce the effectiveness of treatment. In order to improve medicine adherence rates, the study will examine if cognitive behavioral therapy (CBT) therapies can have a favorable effect on patients' motivation, coping techniques, Medication beliefs, reduction in adverse drug reaction (ADRs), Seizures frequency and medication related problems (MRPs) other than adverse drug reaction (ADRs) and overall quality of life of epileptic patients.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: Basic group Lifestyle Modifications: General education about healthy life style and diet. Education : general awareness about disease and medication Pill Planner: Pill planner will be provided to keep them adherent to their medication Counselling: Counsel the patients about there medication dosage, frequency and appropriate time. |
Behavioral: Pharmacist-led Cognitive Behavioral therapy
Pharmacist-led Cognitive Behavioral therapy is patient centered approach that focus both physical and emotional aspect of health is provided. It is focused to identify negative and change negative thought pattern and behavior to improve mental and physical well being.Incorporation education about healthy meal choices, relaxation techniques, self management strategies,to improve education about potential adverse effect, how to recognize and on followup calls how to adjust medication doses along with this is provided.
|
| Experimental: Advanced Lifestyle Modifications: Specific education on keto-diet, yoga and meditation Education : Specific disease education targeting medication adverse drug reaction (ADR), seizure chart management Pill Planner: Pill planner will also be provided to this group Counselling: Cognitive Behavioral therapy will be provided |
Behavioral: Pharmacist-led Cognitive Behavioral therapy
Pharmacist-led Cognitive Behavioral therapy is patient centered approach that focus both physical and emotional aspect of health is provided. It is focused to identify negative and change negative thought pattern and behavior to improve mental and physical well being.Incorporation education about healthy meal choices, relaxation techniques, self management strategies,to improve education about potential adverse effect, how to recognize and on followup calls how to adjust medication doses along with this is provided.
|
Outcome Measures
Primary Outcome Measures
- Medication adherence [3 months]
Adherence will be assessed using (Medication Adherence Reporting Scale) MARS-10. This scale describes three-dimension, Medication adherence behavior (1-4), attitude towards taking medication (5-8), negative side effects and attitudes to psychotropic medication (9-10). Each question has Yes and No response, a response consistent with adherence is coded as 1 and with non-adherence coded as 0. Higher the score higher will be the adherence. Adherence <6 is poor adherence, and >8 is high adherence.
- Quality of life of Epileptic patients [3 months]
Patient's quality of life will be assessed using Quality of life for epilepsy scale(QOLIE-31). QOLIE-31(Quality of life in epilepsy) used for quality-of-life assessment which assess the patient's life's quality level along using anti-epileptic drug (AED) therapy through close ended questions with a score. The score can range from 0-100, with 100 representing the best quality of life.
Secondary Outcome Measures
- Incidence of Drug-Drug Interactions [3 months]
Drug interactions among epileptic and non-epileptic drug will be assessed using standard website (update-Lexicomp) It is used to access the reduction in no. of drug drug interaction after pharmacist intervation in both basic and advance groups.
- Incidence of Adverse reactions [3 months]
Adverse reactions of all anti-epileptic drug will be noted while assessing a patient. It is used to access the reduction in frequency of Adverse drug reaction after pharmacist intervation in both basic and advance groups.
- Rate of seizures per week [3 months]
While assessing patient no. of seizures per week is asked and noted by the pharmacist. After intervening both basic and advance group impact of intervation is accessed for no. of seizures in the groups.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients with confirmed diagnosis.
-
Patients treated for epilepsy with at least one anti epileptic drug, subjects willing to participate in the study with or without other severe co-morbidities were included in the study.
Exclusion Criteria:
-
Pregnant female patients.
-
Patients who provide incomplete information
-
Patients with any terminal disease e.g., end stage renal disease
-
Patients not willing to participate were excluded from the study.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Hamdard University
Investigators
- Study Director: Matti Ullah, PhD, Hamdard University Islamabad Campus
- Principal Investigator: Iqra Farooq, MPhil, Shifa International Hospital
- Study Chair: Muhammad Shafiq, BS. (Hons.), Subhan Medical Trust
- Study Chair: Emmama Jamil, MPhil, Hamdard University Islamabad Campus
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- NA0823